Adamas Pharmaceuticals Inc (ADMS.OQ)
ADMS.OQ on NASDAQ Stock Exchange Global Market
28.09USD
20 Apr 2018
28.09USD
20 Apr 2018
Change (% chg)
$0.42 (+1.52%)
$0.42 (+1.52%)
Prev Close
$27.67
$27.67
Open
$27.67
$27.67
Day's High
$28.33
$28.33
Day's Low
$27.17
$27.17
Volume
296,920
296,920
Avg. Vol
316,486
316,486
52-wk High
$43.98
$43.98
52-wk Low
$13.51
$13.51
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -1.48 | December | 21 Apr 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 4 | 2 | 2 | 2 |
| (2) OUTPERFORM | 7 | 7 | 7 | 7 |
| (3) HOLD | 0 | 0 | 0 | 0 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.64 | 1.78 | 1.78 | 1.78 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 8 | 3.76 | 5.00 | 2.50 | 14.80 |
| Quarter Ending Sep-18 | 8 | 7.38 | 8.00 | 6.20 | 23.00 |
| Year Ending Dec-18 | 10 | 25.54 | 30.00 | 21.70 | 59.54 |
| Year Ending Dec-19 | 9 | 92.13 | 135.00 | 69.20 | 112.31 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 8 | -1.48 | -1.27 | -1.58 | -0.40 |
| Quarter Ending Sep-18 | 8 | -1.50 | -1.36 | -1.68 | -0.14 |
| Year Ending Dec-18 | 10 | -5.80 | -5.25 | -6.57 | -1.74 |
| Year Ending Dec-19 | 9 | -4.01 | -2.68 | -4.58 | -0.48 |
| LT Growth Rate (%) | 1 | 37.70 | 37.70 | 37.70 | -- |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Dec-17 | 0.84 | 0.57 | 0.27 | 32.24 |
| Quarter Ending Sep-17 | 0.03 | 0.00 | 0.03 | 97.00 |
| Quarter Ending Jun-17 | 0.04 | 0.00 | 0.04 | 95.00 |
| Quarter Ending Mar-17 | 0.23 | 0.00 | 0.23 | 100.00 |
| Quarter Ending Dec-16 | 0.19 | 0.04 | 0.16 | 80.96 |
| Earnings (per share) | ||||
| Quarter Ending Dec-17 | -1.18 | -1.27 | 0.09 | -7.73 |
| Quarter Ending Sep-17 | -0.98 | -1.04 | 0.06 | -6.48 |
| Quarter Ending Jun-17 | -0.81 | -0.93 | 0.12 | -15.28 |
| Quarter Ending Mar-17 | -0.71 | -0.72 | 0.01 | -1.88 |
| Quarter Ending Dec-16 | -0.80 | -0.68 | 0.12 | -15.42 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 3.76 | 3.76 | 3.71 | 3.90 | 14.80 |
| Quarter Ending Sep-18 | 7.38 | 7.38 | 7.37 | 6.20 | 23.00 |
| Year Ending Dec-18 | 25.54 | 25.54 | 25.42 | 26.35 | 59.54 |
| Year Ending Dec-19 | 92.13 | 91.45 | 93.15 | 92.09 | 112.31 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | -1.48 | -1.48 | -1.51 | -0.98 | -0.40 |
| Quarter Ending Sep-18 | -1.50 | -1.50 | -1.53 | -0.94 | -0.14 |
| Year Ending Dec-18 | -5.80 | -5.80 | -5.87 | -4.15 | -1.74 |
| Year Ending Dec-19 | -4.01 | -4.03 | -4.11 | -2.59 | -0.48 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 1 | 0 | 1 | 0 |
| Year Ending Dec-19 | 1 | 0 | 0 | 0 |
| Earnings | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-18 | 1 | 0 | 0 | 0 |
| Year Ending Dec-18 | 1 | 1 | 0 | 1 |
| Year Ending Dec-19 | 1 | 0 | 0 | 0 |
Earnings vs. 
Estimates- BRIEF-Adamas Announces Final Results From Phase 3 Open-Label Study Of Gocovri
- BRIEF-Adamas Announces First Patient Enrolled In Phase 3 Trial Of ADS 5102 In Multiple Sclerosis Patients With Walking Impairment
- BRIEF-Adamas Pharmaceuticals Announces Publication Of Data Supporting The Benefits Of Gocovri™ In Parkinson’s Disease Patients With Dyskinesia
- BRIEF-Adamas Pharmaceuticals Says As Of Feb 28, Co Received Prescriptions For Gocovri From About 390 Distinct Prescribers
- BRIEF-Adamas Q4 Loss Per Share $1.27